MAP Kinase p38Inhibitors: Clinical Results and an Intimate Look at Their Interactions with p38α Protein

Author(s): Matthew R. Lee, Celia Dominguez

Journal Name: Current Medicinal Chemistry

Volume 12 , Issue 25 , 2005

Become EABM
Become Reviewer


Mitogen-activated protein kinase p38 is a serine/threonine kinase originally isolated from lipopolysaccharide (LPS) stimulated monocytes. There are four isoforms p38α, p38β, p38γ, and p38δ. The most thoroughly studied isoform is p38α, whose activation has been observed in many hematopoietic and nonhematopoietic cell types upon appropriate stimuli. Subsequently, p38α kinase has been shown to be involved in the biosynthesis of TNFα and IL-1β at the translational and transcriptional level. MAP kinase p38agr; represents a point of convergence for multiple signaling processes that are activated in inflammation and thus a key potential target for the modulation of cytokine production. The discovery and publication of p38α and the pyridinyl-imidazole inhibitor initiated a huge effort by many companies to develop p38α inhibitors as potential treatment for inflammatory diseases. Herein we provide a brief overview of recent reported clinical results for AMG 548, BIRB 796, VX 702, SCIO 469, and SCIO 323. However, our focus will be on the binding modes of these inhibitors and other p38 inhibitors in the recent literature.

Keywords: p38 inhibitors, map kinase, tnfα, il-1β, dgf in, dgf out, amg 548, birb 796, scio 469

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2005
Page: [2979 - 2994]
Pages: 16
DOI: 10.2174/092986705774462914
Price: $65

Article Metrics

PDF: 39